Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
976 stopped studies mapped to Digestive System Carcinoma and descendants · 93% state a reason
Over the 976 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | Phase 2 | withdrawn | Apr 9, 2019 | Louisiana State University Health Sciences Center in New Orleans | Dr. Marshall left UMC and LSU Health Sciences Center. | Other (stated, no rule matched) |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer…(PANTHEON) | Phase 2 | terminated | Nov 6, 2017 | AIO-Studien-gGmbH | slow recruitment | Enrollment / accrual |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | Phase 2 | terminated | Dec 4, 2020 | Zhejiang University | The treatment efficacy was not satisfactory. | Efficacy / futility |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | Phase 2 | terminated | Jul 20, 2020 | SC Liver Research Consortium, LLC | Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity… | Safety / toxicity |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With… | Phase 2 | terminated | Feb 13, 2017 | National Cancer Institute (NCI) | Terminated after an unplanned interim efficacy analysis. | Efficacy / futility |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of…(HiQuality) | Phase 3 | terminated | Jul 6, 2011 | Merit Medical Systems, Inc. | The clinical study was terminated due to the inability to meet target enrollment. | Enrollment / accrual |
| NCT03071094 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic… | Phase 1 / Phase 2 | terminated | Mar 6, 2017 | Transgene | The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab… | Other (stated, no rule matched) |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have… | Phase 2 | withdrawn | Aug 5, 2020 | Boehringer Ingelheim | Not due to safety reasons (sponsor decision). | Safety / toxicity |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | Phase 2 | withdrawn | Jun 5, 2020 | UNC Lineberger Comprehensive Cancer Center | lack of resources | Other (stated, no rule matched) |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed…(GCC 1314) | Phase 2 | terminated | Dec 18, 2014 | University of Maryland, Baltimore | Slow accrual, PI left instituion | Investigator |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in…(DESPARTH) | Phase 1 | terminated | Dec 1, 2014 | University Hospital, Ghent | slow recruitment of patients | Enrollment / accrual |
| NCT04831827 | Promoting Equity for Cancer Screening and Follow-up | N/A | withdrawn | Apr 5, 2021 | Mayo Clinic | Insufficient study resources and change in practice. | Other (stated, no rule matched) |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | Aug 11, 2021 | Fujian Cancer Hospital | We could not get the IRB approval. | Other (stated, no rule matched) |
| NCT01141478 | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San…(HCC) | N/A | terminated | Jun 10, 2010 | Loma Linda University | due to low enrollment | Enrollment / accrual |
| NCT04311047 | Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma…(NANO-PANC) | N/A | terminated | Mar 17, 2020 | Radboud University Medical Center | We decided to stop inclusions and start analysis after 26 inclusions. | Other (stated, no rule matched) |
| NCT03280277 | Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal… | Early Phase 1 | terminated | Sep 12, 2017 | OHSU Knight Cancer Institute | low accrual | Enrollment / accrual |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | Phase 1 | terminated | Feb 22, 2016 | BioNTech Research & Development, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients… | Phase 1 | withdrawn | Jan 16, 2012 | Gilead Sciences | no subjects enrolled | Enrollment / accrual |
| NCT03337776 | Effect of WhatsApp Messenger on Uptake of CRC Screening Study | N/A | withdrawn | Nov 9, 2017 | Chinese University of Hong Kong | COVID | COVID-19 / pandemic |
| NCT03942900 | Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma(LAND) | — | withdrawn | May 8, 2019 | Centre Hospitalier Universitaire de Besancon | Study not submitted to regulatory authorities | Other (stated, no rule matched) |
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | N/A | withdrawn | Aug 13, 2020 | Michael Lidsky, M.D. | No subjects enrolled due to availability of device commercially. | Enrollment / accrual |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | Phase 2 | withdrawn | Jul 1, 2021 | Shanghai Zhongshan Hospital | The standard of care of adjuvant therapy for liver cancer was changed. | Other (stated, no rule matched) |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic… | Phase 2 | withdrawn | Jul 21, 2020 | Jiangsu HengRui Medicine Co., Ltd. | It is difficult to screening subject | Other (stated, no rule matched) |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 2, 2018 | National Cancer Institute (NCI) | Study was closed after one treatment related death. | Other (stated, no rule matched) |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | Phase 1 | terminated | Jun 29, 2017 | University of Chicago | Study stopped due to poor accrual. | Enrollment / accrual |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | Phase 2 | terminated | Dec 16, 2009 | New Mexico Cancer Research Alliance | Low accrual rate | Enrollment / accrual |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced…(PANC-001) | Phase 1 | withdrawn | Feb 17, 2020 | Roger Williams Medical Center | Insufficient accrual rate | Enrollment / accrual |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable…(CIPHER) | Phase 3 | withdrawn | May 24, 2018 | University of Texas Southwestern Medical Center | Due to COVID and other recruitment issues the trial could not be initiated. | COVID-19 / pandemic |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With… | Phase 2 | terminated | Aug 1, 2018 | Chang Gung Memorial Hospital | The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is… | Other (stated, no rule matched) |
| NCT04264754 | Characterization of Methylation Patterns in Hepatocellular Carcinoma | — | terminated | Feb 11, 2020 | Nucleix Ltd. | Sponsor prioritize other clinical projects over this study | Other (stated, no rule matched) |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the…(YES-P) | Phase 3 | terminated | Jun 27, 2013 | Boston Scientific Corporation | Poor Accrual. | Enrollment / accrual |
| NCT02608229 | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | Phase 1 | terminated | Nov 18, 2015 | Washington University School of Medicine | Adverse events | Safety / toxicity |
| NCT03452553 | Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With… | N/A | withdrawn | Mar 2, 2018 | Boston Scientific Corporation | CMS disapproval, no alternative for sites/patient, risk of financial burden. | Funding |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or… | — | terminated | May 3, 2017 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Phase 1 / Phase 2 | withdrawn | Jul 5, 2018 | University of Southern California | No funding | Funding |
| NCT00892255 | Microwave Ablation of Resectable Liver Tumors | — | withdrawn | May 4, 2009 | St. Joseph Hospital of Orange | not stated | Not stated |
| NCT03563274 | QuiremSpheres Observational Study(Hope166) | — | terminated | Jun 20, 2018 | Terumo Europe N.V. | did not meet planned recruitment expectations with a slow recruitment rate | Enrollment / accrual |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | N/A | withdrawn | May 27, 2020 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | Low accrual rate | Enrollment / accrual |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | Phase 3 | withdrawn | Aug 28, 2018 | Istituto Clinico Humanitas | Stopped for internal decisions | Other (stated, no rule matched) |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2014 | Peking University | Because there are questions about adjuvant radiotherapy in this study, the clinical trial is under… | Other (stated, no rule matched) |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | Phase 2 | terminated | Sep 21, 2010 | Medstar Health Research Institute | Study suspended | Other (stated, no rule matched) |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For…(TheraBionics) | Phase 2 | withdrawn | Aug 25, 2020 | Wake Forest University Health Sciences | This application needs further attention in terms of FDA approval and will be reassigned under a… | Other (stated, no rule matched) |
| NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced… | Phase 2 | suspended | Sep 10, 2019 | Zhejiang Cancer Hospital | combination arm delevelped significant poor prognosis | Other (stated, no rule matched) |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo… | Phase 2 | terminated | Oct 6, 2017 | University of Alabama at Birmingham | study was terminated due to poor enrollment | Enrollment / accrual |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | Phase 2 | withdrawn | May 2, 2014 | Zhejiang University | patients not enrolled | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 28, 2022source: clinicaltrials